- Home
- DHAI vs APRE Comparison
DHAI vs APRE Comparison
Compare DHAI & APRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DHAI
- APRE
- Stock Information
- Founded
- DHAI 2007
- APRE 2006
- Country
- DHAI United States
- APRE United States
- Employees
- DHAI N/A
- APRE N/A
- Industry
- DHAI
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DHAI
- APRE Health Care
- Exchange
- DHAI NYSE
- APRE Nasdaq
- Market Cap
- DHAI 10.5M
- APRE 10.0M
- IPO Year
- DHAI N/A
- APRE 2019
- Fundamental
- Price
- DHAI $0.25
- APRE $1.65
- Analyst Decision
- DHAI
- APRE Strong Buy
- Analyst Count
- DHAI 0
- APRE 2
- Target Price
- DHAI N/A
- APRE $15.50
- AVG Volume (30 Days)
- DHAI 6.2M
- APRE 51.7K
- Earning Date
- DHAI 08-18-2025
- APRE 08-11-2025
- Dividend Yield
- DHAI N/A
- APRE N/A
- EPS Growth
- DHAI N/A
- APRE N/A
- EPS
- DHAI N/A
- APRE N/A
- Revenue
- DHAI $69,573,000.00
- APRE $1,284,475.00
- Revenue This Year
- DHAI N/A
- APRE N/A
- Revenue Next Year
- DHAI N/A
- APRE N/A
- P/E Ratio
- DHAI N/A
- APRE N/A
- Revenue Growth
- DHAI 5.40
- APRE 33.27
- 52 Week Low
- DHAI $0.12
- APRE $1.41
- 52 Week High
- DHAI $3.67
- APRE $5.01
- Technical
- Relative Strength Index (RSI)
- DHAI 56.22
- APRE 47.84
- Support Level
- DHAI $0.24
- APRE $1.48
- Resistance Level
- DHAI $0.30
- APRE $1.81
- Average True Range (ATR)
- DHAI 0.04
- APRE 0.15
- MACD
- DHAI 0.00
- APRE -0.01
- Stochastic Oscillator
- DHAI 46.14
- APRE 45.45
About DHAI DIH HOLDINGS US INC
DIH Holding US Inc is a provider of robotic devices used in physical rehabilitation, which incorporate visual stimulation in an interactive manner to enable clinical research and intensive functional rehabilitation and training in patients with walking impairments, reduced balance and/or impaired arm and hand functions. Its products Armeo Power, Armeo Spring, Armeo Spring Pro, etc.
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline products include ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.